ArticleLasers in medical science2025
Combined intraurethral and intravaginal er: YAG laser (UEL + VEL) therapy vs. intraurethral (UEL) alone treatment for stress urinary incontinence? a multicenter retrospective cohort study, real world data from the VELA centers.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to compare the efficacy of the combined intraurethral and intravaginal (UEL + VEL) non-ablative Erbium (Er): YAG laser with UEL alone in improving the symptoms of stress urinary incontinence (SUI) and/or stress-dominant mixed urinary incontinence (MUI) in women.This retrospective, multicenter cohort study included 228 women with SUI and/or MUI, with 161 women in the UEL + VEL group and 67 in the UEL group. The primary outcome was the change International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form (ICIQ-UI SF) scores at baseline and at 3, 6, and 12 months.Demographic characteristics, including age, body mass index (BMI), and menopausal duration, were similar between the groups, with the exception of parity, which was significantly higher in the UEL group (2.49 ± 1.15 vs. 2.01 ± 1.15, p = 0.025). Baseline ICIQ-UI SF scores were significantly higher in the UEL + VEL group (12.08 ± 4.17 vs. 10.35 ± 4.95, p = 0.008). Over time, the UEL + VEL group showed a steeper and more substantial decline in symptom scores, eventually converging with the UEL group at 12 months. The UEL group, starting with lower baseline scores, showed a more moderate decline. This suggests that UEL + VEL might be more effective in reducing symptoms over time. Within-subjects test indicated that parity significantly influenced symptom improvement over time (p < 0.001, F = 13.843), and between-subjects test at 12 months showed that treatment type (p = 0.036, F = 4.479), parity (p = 0.002, F = 10.029), and their interaction (p = 0.022, F = 5.333). were significant predictors of outcome.Both UEL and combined UEL + VEL applications significantly improved UI symptoms up to 12 months. However, UEL + VEL was more effective overall. Parity was a significant factor influencing the treatment outcome, suggesting that increasing parity may be a prognostic factor in laser therapy for UI.
Indexed as
Identifiers
41060452What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.